AR065640A1 - Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma - Google Patents

Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma

Info

Publication number
AR065640A1
AR065640A1 ARP080100948A ARP080100948A AR065640A1 AR 065640 A1 AR065640 A1 AR 065640A1 AR P080100948 A ARP080100948 A AR P080100948A AR P080100948 A ARP080100948 A AR P080100948A AR 065640 A1 AR065640 A1 AR 065640A1
Authority
AR
Argentina
Prior art keywords
lyophilized preparation
preparation
iii
influenza vaccine
liofilized
Prior art date
Application number
ARP080100948A
Other languages
English (en)
Inventor
Chikamasa Yamashita
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR065640A1 publication Critical patent/AR065640A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un preparado liofilizado en el cual la vacuna contra la influenza presenta una estabilidad mejorada. Un preparado liofilizado en el cual la vacuna contra la influenza presenta estabilidad significativamente mejorada puede ser obtenido liofilizandouna solucion acuosa que cumple con las siguientes condiciones (A) a (C) en la preparacion de un preparado liofilizado que contiene una vacuna contra la influenza: (A) se incorporan (i) una vacuna contra la influenza, (ii) un aminoácido hidrofobo y(iii) arginina y una sal de adicion de acido de la misma: (B) la proporcion del componente (iii) es de 20 a 85% en peso con relacion a la cantidad total del preparado liofilizado resultante; y (C) el pH es ajustado para ser de 8 a 10 controlando laproporcion de arginia y una sal de adicion de acido de la misma que forma el componente (iii). Reivindicacion 3: un preparado liofilizado de acuerdo con la reivindicacion 1, caracterizado porque el (ii) aminoácido hibrofobo es fenilalanina, o unacombinacion de fenilalanina con por lo menos uno de valina, leucina e isoleucina. Reivindicacion 9: un preparado liofilizado de acuerdo con la reivindicacion 1, que es un preparado farmaceutico para la administracion transpulmonar. Reivindicacion10: un preparado liofilizado de acuerdo con la reivindicacion 1, que es en preparado farmaceutico para la administracion nasal.
ARP080100948A 2007-03-09 2008-03-07 Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma AR065640A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007059724 2007-03-09

Publications (1)

Publication Number Publication Date
AR065640A1 true AR065640A1 (es) 2009-06-17

Family

ID=39759470

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100948A AR065640A1 (es) 2007-03-09 2008-03-07 Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma

Country Status (20)

Country Link
US (1) US8216588B2 (es)
EP (1) EP2119451A4 (es)
JP (1) JP5388842B2 (es)
KR (1) KR20090128463A (es)
CN (1) CN101631563B (es)
AR (1) AR065640A1 (es)
AU (1) AU2008225501B2 (es)
BR (1) BRPI0808037A2 (es)
CA (1) CA2680193C (es)
HK (1) HK1139076A1 (es)
IL (1) IL200588A0 (es)
MX (1) MX2009009635A (es)
MY (1) MY149924A (es)
NZ (1) NZ579395A (es)
RU (1) RU2484847C2 (es)
SG (1) SG179406A1 (es)
TW (1) TWI428140B (es)
UA (1) UA97391C2 (es)
WO (1) WO2008111532A1 (es)
ZA (1) ZA200905952B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
CN108588035A (zh) * 2011-06-28 2018-09-28 白血球保健股份有限公司 病毒或细菌的新型稳定方法
ES2659066T3 (es) * 2013-01-25 2018-03-13 Wintermute Biomedical, Inc. Compuestos terapéuticos
GB201314248D0 (en) * 2013-08-08 2013-09-25 Glaxosmithkline Biolog Sa Saccharide vaccine formulation
CA2923010C (en) 2013-09-03 2022-08-30 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
EP3060247A1 (en) * 2013-10-25 2016-08-31 Leukocare Ag A novel method for the production of stabile vaccines
TW201722478A (zh) * 2015-11-27 2017-07-01 Nitto Denko Corp 流感疫苗乾燥製劑、及流感疫苗乾燥製劑之製造方法
WO2017090766A1 (ja) 2015-11-27 2017-06-01 日東電工株式会社 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法
EP3381468A4 (en) * 2015-11-27 2019-06-05 Nitto Denko Corporation DRIED INFLUENZA VACCINE PREPARATION AND METHOD FOR PRODUCING A DRIED INFLUENZED VACCINE PREPARATION
AU2018217906A1 (en) 2017-02-13 2019-08-15 Wintermute Biomedical, Inc. Anti-pathogenic therapeutic compositions
KR20210108942A (ko) 2018-10-01 2021-09-03 윈터뮤트 바이오메디컬 인코포레이티드 치료 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4537769A (en) 1982-04-06 1985-08-27 American Cyanamid Company Stabilization of influenza virus vaccine
JPH07121871B2 (ja) * 1986-10-09 1995-12-25 国立予防衛生研究所長 インフルエンザワクチン凍結乾燥製剤
JPH05229960A (ja) * 1990-10-30 1993-09-07 Dai Ichi Seiyaku Co Ltd 新規インフルエンザワクチン
JPH0813753B2 (ja) * 1992-05-22 1996-02-14 株式会社微生物化学研究所 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ３型ウイルス感染症、牛ｒｓウイルス感染症および牛アデノ７型ウイルス感染症５種混合生ワクチン
MXPA02009485A (es) 2000-03-31 2003-03-10 Kirin Brewery Preparacion en polvo para administracion a traves de la mucosa, que comprende un farmaco de alto peso molecular y que muestra una estabilidad mejorada en almacenamiento.
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
JP2004054555A (ja) * 2002-07-19 2004-02-19 Yokogawa Electric Corp 表示装置
KR101190932B1 (ko) * 2003-02-25 2012-10-16 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
ES2633471T3 (es) * 2004-10-06 2017-09-21 Medimmune, Llc Composiciones de vacuna contra la gripe estables a temperatura de refrigerador
RU2290205C1 (ru) * 2005-09-13 2006-12-27 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунологическим препаратам "МИКРОГЕН" Министерства здравоохранения Российской Федерации Способ получения живой вакцины для профилактики гриппа

Also Published As

Publication number Publication date
US20100104595A1 (en) 2010-04-29
UA97391C2 (ru) 2012-02-10
MY149924A (en) 2013-10-31
CN101631563A (zh) 2010-01-20
EP2119451A4 (en) 2012-05-16
EP2119451A1 (en) 2009-11-18
IL200588A0 (en) 2010-05-17
RU2484847C2 (ru) 2013-06-20
SG179406A1 (en) 2012-04-27
AU2008225501B2 (en) 2013-08-29
JP5388842B2 (ja) 2014-01-15
TWI428140B (zh) 2014-03-01
KR20090128463A (ko) 2009-12-15
MX2009009635A (es) 2009-09-22
CA2680193C (en) 2015-05-05
WO2008111532A1 (ja) 2008-09-18
TW200848074A (en) 2008-12-16
AU2008225501A1 (en) 2008-09-18
ZA200905952B (en) 2010-11-24
CA2680193A1 (en) 2008-09-18
RU2009137380A (ru) 2011-04-20
AU2008225501A2 (en) 2009-09-24
HK1139076A1 (en) 2010-09-10
JPWO2008111532A1 (ja) 2010-06-24
CN101631563B (zh) 2013-07-24
US8216588B2 (en) 2012-07-10
BRPI0808037A2 (pt) 2014-06-17
NZ579395A (en) 2012-05-25

Similar Documents

Publication Publication Date Title
AR065640A1 (es) Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma
BR112013022213A2 (pt) administração parenteral de tapentadol
JP2017533218A5 (es)
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
PE20121517A1 (es) Compuestos lipopeptidos y metodos relacionados
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
BR112014019667A2 (pt) formulação de anticorpo abeta
BR112015000615A2 (pt) purinas macrocíclicas para o tratamento de infecções virais
MY156188A (en) Long - acting formulations of insulins
AR077225A1 (es) Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza
BR112015011179A8 (pt) composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação
GT201400027A (es) Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina
AR083366A1 (es) Formulaciones para el tratamiento de las afecciones de las vias aereas superiores
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
PE20130728A1 (es) Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
RU2014101036A (ru) Стабилизированная композиция вориконазола
AR096854A1 (es) Composición farmacéutica para una liberación sostenida de lanreotide
BR112014009242A2 (pt) nanossuspensão farmacêutica
BR112022002582A2 (pt) Sais de peptídeo hidrofóbicos para composições de liberação prolongada
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno
BR112013024801A2 (pt) formulações de otamixaban com estabilidade aprimorada
ECSP11010856A (es) Composición farmacéutica sólida

Legal Events

Date Code Title Description
FB Suspension of granting procedure